PF-04518600
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for PF-04518600, covering 2022-04-21 to 2025-10-14. Get the full timeline:
Most recent: Clinical Trial Update: Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies [Phase 1, Phase 2]